EditorialThe model-based approach to clinical studies in particle radiotherapy – A new concept in evidence based radiation oncology?
References (25)
- et al.
Intensity modulated proton therapy for postmastectomy radiation of bilateral implant reconstructed breasts: a treatment planning study
Radiother Oncol
(2013) - et al.
Helical tomotherapy and intensity modulated proton therapy in the treatment of dominant intraprostatic lesion: a treatment planning comparison
Radiother Oncol
(2013) - et al.
Adjuvant radiation therapy for early stage seminoma: proton versus photon planning comparison and modeling of second cancer risk
Radiother Oncol
(2012) - et al.
Carbon ion radiotherapy for localized primary sarcoma of the extremities: Results of a phase I/II trial
Radiother Oncol
(2012) - et al.
Comparison of intensity-modulated radiotherapy, adaptive radiotherapy, proton radiotherapy, and adaptive proton radiotherapy for treatment of locally advanced head and neck cancer
Radiother Oncol
(2011) - et al.
Secondary radiation doses of intensity-modulated radiotherapy and proton beam therapy in patients with lung and liver cancer
Radiother Oncol
(2011) - et al.
Potentials of robust intensity modulated scanning proton plans for locally advanced lung cancer in comparison to intensity modulated photon plans
Radiother Oncol
(2012) - et al.
Irradiation with protons for the individualized treatment of patients with locally advanced rectal cancer: a planning study with clinical implications
Radiother Oncol
(2012) - et al.
Helical tomotherapy and intensity modulated proton therapy in the treatment of early stage prostate cancer: a treatment planning comparison
Radiother Oncol
(2011) - et al.
Controversies in clinical trials in proton radiotherapy: the present and the future
Semin Radiat Oncol
(2013)
Charged particles in radiotherapy: a 5-year update of a systematic review
Radiother Oncol
A systematic literature review of the clinical and cost-effectiveness of hadron therapy in cancer
Radiother Oncol
Cited by (19)
Optimal Allocation of Proton Therapy Slots in Combined Proton-Photon Radiation Therapy
2021, International Journal of Radiation Oncology Biology PhysicsCitation Excerpt :Consequently, only a small percentage of patients with an indication for radiation therapy are treated with protons,7 and not all patients who may benefit from proton therapy have access to it.8 Strategies for selecting patients for proton therapy vary among institutions, countries, and health care systems.9-15 In most countries, several treatments are considered standard indications for proton therapy, including pediatric patients and tumors in the proximity of the base of the skull or the spinal cord (eg, chordoma and chondrosarcoma).9,15,16
Clinical practice vs. state-of-the-art research and future visions: Report on the 4D treatment planning workshop for particle therapy – Edition 2018 and 2019
2021, Physica MedicaCitation Excerpt :Although several RCTs are currently ongoing around the world, the necessity of long-term follow up of tumor progression and side effects limits the feasibility of their use in rapid technological evolution of 4D proton therapy. The model-based approach is an alternative method of defining which patients would receive the greatest clinical gain from selected therapy [23–24]. It is based on comparative evaluations of photon and proton plans with regard to radiation toxicity predicted by normal tissue complication probability (NTCP) models.
Integrating Mathematical Modeling into the Roadmap for Personalized Adaptive Radiation Therapy
2019, Trends in CancerCitation Excerpt :A mathematical model suggested that this new treatment technique could decrease overall radiation-induced toxicity to feathered OARs or be used to increase the total dose to the tumor if needed without additional OAR toxicity compared with standard RT plans. With the same aim of reducing OAR toxicity, a NTCP-based approach has been recently proposed to select patients that would benefit from proton therapy rather than photon therapy [31,32]. Although this method has already been adopted by the Dutch Health Council and the Dutch Health Care Insurance Board, efforts are still needed to collect clinical radiobiology data to include routine morbidity assessments and further evaluation of the NTCP thresholds in the selection criteria and to find optimal models that balance data fit and predictability [33].
Union of light ion therapy centers in Europe (ULICE EC FP7) – Objectives and achievements of joint research activities
2018, Radiotherapy and OncologyCitation Excerpt :Currently it is still subject of investigation on which criteria an attending physician should base a final decision regarding the treatment modality for an individual patient. One practical solution is a direct comparison of patient specific dose distributions to discriminate between treatment options [48,49]. This may also include the application of available state-of-the-art tumor control probability and normal tissue complication probability models [50,51].
“Radiobiology of Proton Therapy”: Results of an international expert workshop
2018, Radiotherapy and OncologyCitation Excerpt :It does, however, pose challenges in terms of the required accuracy of the underlying models [81,82]. Secondly, development and validation of thresholds for NTCP reduction is critical for selection and can introduce tremendous heterogeneity in clinical trials [83]. There are various clinical situations in which patients would benefit from proton therapy and where dose planning studies suggest a potential for improved outcome [84].